Young doctor working

2014 Financial results

Second quarter and half year results 2014

Pascal Soriot, Chief Executive Officer, commenting on the results, said:

"We have made significant progress in the first half of the year, with visible momentum across our cardiovascular, diabetes and respiratory franchises as well as strong growth in the emerging markets. This has driven revenue growth for the second consecutive quarter and achieved a 13% increase in Core EPS in the quarter. The pace of execution of our strategy and the underlying performance of our teams give us confidence to raise 2014 guidance for the full year.

“The business combination with Almirall will offer strategic long-term value, bringing together the two innovative portfolios to strengthen further our commitment to respiratory disease and contribute to our growth.

“We now have one of the most exciting pipelines in the industry with 14 assets in late stage development. Over recent weeks, we have presented compelling data that demonstrate our potential to significantly advance the way patients are treated, including in immuno-oncology. The quality of transformation we are seeing across all core areas of our business further underpins our confidence in AstraZeneca's longer term prospects.”

Teleconference replay

A recording of the analyst presentation and Q&A session will be available until 13:30 BST Wednesday 13 August on the following numbers:

LocationNumberConference ID
UK local 0800 953 1533 29614047#
US (freephone) 1 866 247 4222 29614047#
International +44 (0) 1452 55 00 00 29614047#

 

Keeping investors in touch

Download our iPad app now from the app store

The AstraZeneca Investor Relations iPad app provides instant access to our latest news, webcasts and presentations, events and leadership videos.

Download and install from the iTunes store